The global Chronic Heart Failure Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chronic Heart Failure Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Heart Failure Treatment.
Report Scope
The Chronic Heart Failure Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Heart Failure Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Heart Failure Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Medtronic
Abbott
Johnson & Johnson
Merck
Stanley Pharmaceuticals
New Haven Pharmaceuticals, Inc.
Boston Scientific Corporation
HeartWare
Pfizer
GlaxoSmithKline plc
Novartis International AG
Biovail Corporation
Bristol-Myers Squibb Company
Abiomed
Symplmed Pharmaceuticals
Berlin Heart GmbH
ReliantHeart, Inc.
Cardiokinetix
Biotronik
Jarvik Heart
Segment by Type
ICDs
VADs
Drugs
Others
Segment by Application
Hospital
Clinic
Household
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Heart Failure Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Heart Failure Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 ICDs
1.2.3 VADs
1.2.4 Drugs
1.2.5 Others
1.3 Market by Application
1.3.1 Global Chronic Heart Failure Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Household
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Heart Failure Treatment Market Perspective (2019-2030)
2.2 Chronic Heart Failure Treatment Growth Trends by Region
2.2.1 Global Chronic Heart Failure Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Chronic Heart Failure Treatment Historic Market Size by Region (2019-2024)
2.2.3 Chronic Heart Failure Treatment Forecasted Market Size by Region (2025-2030)
2.3 Chronic Heart Failure Treatment Market Dynamics
2.3.1 Chronic Heart Failure Treatment Industry Trends
2.3.2 Chronic Heart Failure Treatment Market Drivers
2.3.3 Chronic Heart Failure Treatment Market Challenges
2.3.4 Chronic Heart Failure Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Heart Failure Treatment Players by Revenue
3.1.1 Global Top Chronic Heart Failure Treatment Players by Revenue (2019-2024)
3.1.2 Global Chronic Heart Failure Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Chronic Heart Failure Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Heart Failure Treatment Revenue
3.4 Global Chronic Heart Failure Treatment Market Concentration Ratio
3.4.1 Global Chronic Heart Failure Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Heart Failure Treatment Revenue in 2023
3.5 Chronic Heart Failure Treatment Key Players Head office and Area Served
3.6 Key Players Chronic Heart Failure Treatment Product Solution and Service
3.7 Date of Enter into Chronic Heart Failure Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Heart Failure Treatment Breakdown Data by Type
4.1 Global Chronic Heart Failure Treatment Historic Market Size by Type (2019-2024)
4.2 Global Chronic Heart Failure Treatment Forecasted Market Size by Type (2025-2030)
5 Chronic Heart Failure Treatment Breakdown Data by Application
5.1 Global Chronic Heart Failure Treatment Historic Market Size by Application (2019-2024)
5.2 Global Chronic Heart Failure Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Chronic Heart Failure Treatment Market Size (2019-2030)
6.2 North America Chronic Heart Failure Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Chronic Heart Failure Treatment Market Size by Country (2019-2024)
6.4 North America Chronic Heart Failure Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Heart Failure Treatment Market Size (2019-2030)
7.2 Europe Chronic Heart Failure Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Chronic Heart Failure Treatment Market Size by Country (2019-2024)
7.4 Europe Chronic Heart Failure Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Heart Failure Treatment Market Size (2019-2030)
8.2 Asia-Pacific Chronic Heart Failure Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Chronic Heart Failure Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Chronic Heart Failure Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Heart Failure Treatment Market Size (2019-2030)
9.2 Latin America Chronic Heart Failure Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Chronic Heart Failure Treatment Market Size by Country (2019-2024)
9.4 Latin America Chronic Heart Failure Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Heart Failure Treatment Market Size (2019-2030)
10.2 Middle East & Africa Chronic Heart Failure Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Chronic Heart Failure Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Chronic Heart Failure Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Medtronic
11.1.1 Medtronic Company Detail
11.1.2 Medtronic Business Overview
11.1.3 Medtronic Chronic Heart Failure Treatment Introduction
11.1.4 Medtronic Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.1.5 Medtronic Recent Development
11.2 Abbott
11.2.1 Abbott Company Detail
11.2.2 Abbott Business Overview
11.2.3 Abbott Chronic Heart Failure Treatment Introduction
11.2.4 Abbott Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.2.5 Abbott Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Chronic Heart Failure Treatment Introduction
11.3.4 Johnson & Johnson Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.3.5 Johnson & Johnson Recent Development
11.4 Merck
11.4.1 Merck Company Detail
11.4.2 Merck Business Overview
11.4.3 Merck Chronic Heart Failure Treatment Introduction
11.4.4 Merck Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.4.5 Merck Recent Development
11.5 Stanley Pharmaceuticals
11.5.1 Stanley Pharmaceuticals Company Detail
11.5.2 Stanley Pharmaceuticals Business Overview
11.5.3 Stanley Pharmaceuticals Chronic Heart Failure Treatment Introduction
11.5.4 Stanley Pharmaceuticals Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.5.5 Stanley Pharmaceuticals Recent Development
11.6 New Haven Pharmaceuticals, Inc.
11.6.1 New Haven Pharmaceuticals, Inc. Company Detail
11.6.2 New Haven Pharmaceuticals, Inc. Business Overview
11.6.3 New Haven Pharmaceuticals, Inc. Chronic Heart Failure Treatment Introduction
11.6.4 New Haven Pharmaceuticals, Inc. Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.6.5 New Haven Pharmaceuticals, Inc. Recent Development
11.7 Boston Scientific Corporation
11.7.1 Boston Scientific Corporation Company Detail
11.7.2 Boston Scientific Corporation Business Overview
11.7.3 Boston Scientific Corporation Chronic Heart Failure Treatment Introduction
11.7.4 Boston Scientific Corporation Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.7.5 Boston Scientific Corporation Recent Development
11.8 HeartWare
11.8.1 HeartWare Company Detail
11.8.2 HeartWare Business Overview
11.8.3 HeartWare Chronic Heart Failure Treatment Introduction
11.8.4 HeartWare Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.8.5 HeartWare Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Chronic Heart Failure Treatment Introduction
11.9.4 Pfizer Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 GlaxoSmithKline plc
11.10.1 GlaxoSmithKline plc Company Detail
11.10.2 GlaxoSmithKline plc Business Overview
11.10.3 GlaxoSmithKline plc Chronic Heart Failure Treatment Introduction
11.10.4 GlaxoSmithKline plc Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.10.5 GlaxoSmithKline plc Recent Development
11.11 Novartis International AG
11.11.1 Novartis International AG Company Detail
11.11.2 Novartis International AG Business Overview
11.11.3 Novartis International AG Chronic Heart Failure Treatment Introduction
11.11.4 Novartis International AG Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.11.5 Novartis International AG Recent Development
11.12 Biovail Corporation
11.12.1 Biovail Corporation Company Detail
11.12.2 Biovail Corporation Business Overview
11.12.3 Biovail Corporation Chronic Heart Failure Treatment Introduction
11.12.4 Biovail Corporation Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.12.5 Biovail Corporation Recent Development
11.13 Bristol-Myers Squibb Company
11.13.1 Bristol-Myers Squibb Company Company Detail
11.13.2 Bristol-Myers Squibb Company Business Overview
11.13.3 Bristol-Myers Squibb Company Chronic Heart Failure Treatment Introduction
11.13.4 Bristol-Myers Squibb Company Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.13.5 Bristol-Myers Squibb Company Recent Development
11.14 Abiomed
11.14.1 Abiomed Company Detail
11.14.2 Abiomed Business Overview
11.14.3 Abiomed Chronic Heart Failure Treatment Introduction
11.14.4 Abiomed Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.14.5 Abiomed Recent Development
11.15 Symplmed Pharmaceuticals
11.15.1 Symplmed Pharmaceuticals Company Detail
11.15.2 Symplmed Pharmaceuticals Business Overview
11.15.3 Symplmed Pharmaceuticals Chronic Heart Failure Treatment Introduction
11.15.4 Symplmed Pharmaceuticals Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.15.5 Symplmed Pharmaceuticals Recent Development
11.16 Berlin Heart GmbH
11.16.1 Berlin Heart GmbH Company Detail
11.16.2 Berlin Heart GmbH Business Overview
11.16.3 Berlin Heart GmbH Chronic Heart Failure Treatment Introduction
11.16.4 Berlin Heart GmbH Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.16.5 Berlin Heart GmbH Recent Development
11.17 ReliantHeart, Inc.
11.17.1 ReliantHeart, Inc. Company Detail
11.17.2 ReliantHeart, Inc. Business Overview
11.17.3 ReliantHeart, Inc. Chronic Heart Failure Treatment Introduction
11.17.4 ReliantHeart, Inc. Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.17.5 ReliantHeart, Inc. Recent Development
11.18 Cardiokinetix
11.18.1 Cardiokinetix Company Detail
11.18.2 Cardiokinetix Business Overview
11.18.3 Cardiokinetix Chronic Heart Failure Treatment Introduction
11.18.4 Cardiokinetix Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.18.5 Cardiokinetix Recent Development
11.19 Biotronik
11.19.1 Biotronik Company Detail
11.19.2 Biotronik Business Overview
11.19.3 Biotronik Chronic Heart Failure Treatment Introduction
11.19.4 Biotronik Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.19.5 Biotronik Recent Development
11.20 Jarvik Heart
11.20.1 Jarvik Heart Company Detail
11.20.2 Jarvik Heart Business Overview
11.20.3 Jarvik Heart Chronic Heart Failure Treatment Introduction
11.20.4 Jarvik Heart Revenue in Chronic Heart Failure Treatment Business (2019-2024)
11.20.5 Jarvik Heart Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Medtronic
Abbott
Johnson & Johnson
Merck
Stanley Pharmaceuticals
New Haven Pharmaceuticals, Inc.
Boston Scientific Corporation
HeartWare
Pfizer
GlaxoSmithKline plc
Novartis International AG
Biovail Corporation
Bristol-Myers Squibb Company
Abiomed
Symplmed Pharmaceuticals
Berlin Heart GmbH
ReliantHeart, Inc.
Cardiokinetix
Biotronik
Jarvik Heart
*If Applicable.